JP6847044B2 - 肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法 - Google Patents

肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法 Download PDF

Info

Publication number
JP6847044B2
JP6847044B2 JP2017547514A JP2017547514A JP6847044B2 JP 6847044 B2 JP6847044 B2 JP 6847044B2 JP 2017547514 A JP2017547514 A JP 2017547514A JP 2017547514 A JP2017547514 A JP 2017547514A JP 6847044 B2 JP6847044 B2 JP 6847044B2
Authority
JP
Japan
Prior art keywords
cells
pancreatic endocrine
subject
mice
transplantation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017547514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507889A5 (https=
JP2018507889A (ja
Inventor
ティモシー・ジェイ・キーファー
ジェニファー・イー・ブルーイン
Original Assignee
シーシーエス・ベンチャーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーシーエス・ベンチャーズ・リミテッド filed Critical シーシーエス・ベンチャーズ・リミテッド
Publication of JP2018507889A publication Critical patent/JP2018507889A/ja
Publication of JP2018507889A5 publication Critical patent/JP2018507889A5/ja
Application granted granted Critical
Publication of JP6847044B2 publication Critical patent/JP6847044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017547514A 2015-03-11 2016-03-11 肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法 Active JP6847044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131540P 2015-03-11 2015-03-11
US62/131,540 2015-03-11
PCT/CA2016/000072 WO2016141460A1 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Publications (3)

Publication Number Publication Date
JP2018507889A JP2018507889A (ja) 2018-03-22
JP2018507889A5 JP2018507889A5 (https=) 2019-04-18
JP6847044B2 true JP6847044B2 (ja) 2021-03-24

Family

ID=56879832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017547514A Active JP6847044B2 (ja) 2015-03-11 2016-03-11 肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法

Country Status (7)

Country Link
US (2) US10772917B2 (https=)
EP (1) EP3268016B1 (https=)
JP (1) JP6847044B2 (https=)
CN (1) CN107530379A (https=)
AU (1) AU2016228894B2 (https=)
CA (1) CA2979293C (https=)
WO (1) WO2016141460A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951136B2 (en) 2017-12-12 2024-04-09 The Regents Of The University Of California Preservation of pancreatic islet grafts in the extrahepatic space
US11530211B2 (en) 2018-01-18 2022-12-20 Daiichi Sankyo Company, Limited Dihydroindolizinone derivative
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
JP7617033B2 (ja) 2019-05-22 2025-01-17 ザ クリーブランド クリニック ファウンデーション 背側前腸及び前方ドメイン内胚葉細胞の生成
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
KR20050044393A (ko) * 2001-11-09 2005-05-12 아르테셀 사이언스, 인크. 지방 조직 유래된 스트로마 세포의 내분비 췌장 분화 및이의 용도
CA2494134A1 (en) * 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
AU2003268534A1 (en) * 2002-09-06 2004-03-29 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
EP2399990B1 (en) 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
JP2006149380A (ja) * 2004-10-27 2006-06-15 Kobe Univ 遺伝子改変動物の新規用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
WO2008054716A2 (en) * 2006-10-31 2008-05-08 National Stem Cell Holding Inc. Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata
DK2089005T3 (da) * 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
EP2229434B1 (en) 2007-11-27 2011-09-07 Lifescan, Inc. Differentiation of human embryonic stem cells
WO2009137844A2 (en) * 2008-05-09 2009-11-12 Vistagen Therapeutics, Inc. Pancreatic endocrine progenitor cells derived from pluripotent stem cells
EP2395988A2 (en) * 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
ES2665006T3 (es) 2009-10-29 2018-04-24 Janssen Biotech, Inc. Células madre pluripotentes
WO2011160066A1 (en) * 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
US20120039955A1 (en) * 2010-08-12 2012-02-16 Janssen Biotech, Inc. Treatment of Diabetes with Pancreatic Endocrine Precursor Cells
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Also Published As

Publication number Publication date
US10772917B2 (en) 2020-09-15
JP2018507889A (ja) 2018-03-22
US20210015872A1 (en) 2021-01-21
CA2979293C (en) 2022-01-04
AU2016228894A1 (en) 2017-11-02
WO2016141460A1 (en) 2016-09-15
US20180055890A1 (en) 2018-03-01
EP3268016B1 (en) 2021-04-28
AU2016228894B2 (en) 2021-03-04
EP3268016A4 (en) 2018-12-12
CA2979293A1 (en) 2016-09-15
EP3268016A1 (en) 2018-01-17
CN107530379A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
JP6847044B2 (ja) 肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法
Silva et al. Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges
US11827905B2 (en) SC-beta cells and compositions and methods for generating the same
KR102167396B1 (ko) 줄기세포용 배양 배지
JP2021516066A (ja) 幹細胞のベータ細胞への分化を促進する方法
Arutyunyan et al. Regenerative medicine of pancreatic islets
KR20200087201A (ko) 섬세포 제조 조성물 및 사용 방법
Kim et al. Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells
JP2025505582A (ja) 糖尿病の細胞治療
CN118355109A (zh) 从多能干细胞生成功能性胰岛的方法
Dave Extrinsic factors promoting insulin producing cell-differentiation and insulin expression enhancement-hope for diabetics.
Beamish Islet identity in transplantation procedures: The intersection of cellular maturity and function
Samuelson Sca-1 positive pancreatic progenitor cells: a replacement for transplanted islets
Tadros Induction of human pancreatic mesenchymal stem cells to insulin producing cells for the treatment of type 1 diabetes
Monfrini Characterization of Mesenchymal Stem Cells effect on Pancreatic Islets: a tool for Type 1 Diabetes Therapy
McCulloch Phenotypic analysis of human stem cells and their differentiation potential towards pancreatic cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171128

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210302

R150 Certificate of patent or registration of utility model

Ref document number: 6847044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250